Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

N-terminal Pro-B-type Natriuretic Peptide as a Predictive Risk Factor in Fontan Operation

Fontan 수술시 위험 예측인자로서의 N-Terminal Pro-B-type Natriuretic Peptide의 유용성

  • Received : 2005.07.04
  • Accepted : 2005.09.08
  • Published : 2005.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study aimed to investigate the correlation between the plasma level of N-terminal pro-B-type natriuretic peptide(pro-BNP) and several known risk factors influencing outcomes after Fontan operations, and to assess whether pro-BNP levels can be used as predictive risk factors in Fontan operations. Methods : Plasma pro-BNP concentrations were measured in 35 patients with complex cardiac anomalies before catheterization. Cardiac catheterization was performed in all subjects. Mean right atrium pressure, mean pulmonary artery pressure(PAP), and ventricular end-diastolic pressure(EDP) were obtained. Cardiac output and pulmonary vascular resistance were calculated by Fick method. Results : Plasma pro-BNP levels exhibited statistically significant positive correlations with mean PAP(r=0.70, P<0.001), pulmonary vascular resistance(r=0.57, P<0.001), RVEDP(r=0.63, P<0.001), LVEDP(r=0.74, P<0.001), and cardiothoracic ratio(r=0.71, P<0.001). The area under the ROC curve using pro-BNP level to differentiate risk groups in Fontan operations was high : 0.868(95 percent CI, 0.712-1.023, P<0.01). The cutoff value of pro-BNP concentrations for the detection of risk groups in Fontan operations was determined to be 332.4 pg/mL(sensitivity 83.3 percent, specificity 82.7 percent). Conclusion : These data suggest that plasma pro-BNP levels may be used as a predictive risk factor in Fontan operations, and as a guide to determine the mode of therapy during follow-up after Fontan operations.

목 적 : 복잡심장기형 환자에 대한 폰탄 수술 기법이 도입되면서 복잡심장기형 환자의 생존율의 향상 및 유병률의 저하가 이루어졌지만, 폰탄 수술 후의 유병률과 사망률은 여전히 해결해야할 과제로 남아 있다. 폰탄 수술 후 임상경과에 영향을 미치는 위험요소는 여러 가지를 들 수 있지만, 아직도 정립이 되어 있지 않은 실정이다. 본 연구는 폰탄 수술시 이미 알려져 있는 위험요소들과 심실기능부전의 새로운 지표인 BNP와의 관련성을 알아보고, 복잡심장기형 환자의 폰탄 수술시 위험요소로서의 BNP의 적합성과 효용성을 알아보고자 하였다. 방 법 : 2004년 6월부터 12월까지 세종병원에 입원한 복잡심장기형 환자를 대상으로 하였다. 심도자검사를 통하여 폐동맥압력, 심실의 이완말기압력, 폐혈관저항 및 심박출량 등을 구하였고, 심도자검사 전 말초 정맥혈을 채취하여 pro-BNP 농도를 측정하였다. 결 과 : 대상환자는 총 35명으로 남자가 21명, 여자가 14명이었으며, 연령 분포는 4개월에서 16세(중간값 : 4.7세)이었다. 심장질환으로는 단심실(11명), 양대혈관 우심실기시(9명), heterotaxy 증후군(4명), 삼첨판폐쇄(3명), 수정대혈관전위(3명), 심실중격결손이 없는 폐동맥폐쇄(2명), 그 외 심장질환(3명) 등이 있었다. 평균 폐동맥압력이 18 mmHg 미만인 환자의 pro-BNP 농도의 중간값은 172.6 pg/mL, 평균 폐동맥압력이 18 mmHg 이상인 환자의 pro-BNP 농도의 중간값은 1,457 pg/mL으로, 두 군간의 유의한 pro-BNP 농도의 차이를 보였다(P<0.05). 또한 평균 폐동맥압력이 높을수록 혈장 pro-BNP 농도가 높은 의미 있는 양의 상관관계를 보여 주었다(r=0.70, P<0.001). 폐혈관저항이 3 Wu 미만인 환자의 혈장 pro-BNP 농도의 중간값은 190.6 pg/mL, 폐혈관저항이 3 Wu 이상인 환자의 혈장 pro-BNP 농도의 중간값은 335.2 pg/mL으로 두 군간의 유의한 pro-BNP의 농도의 차이를 보였다(P<0.05). 또한 폐혈관저항이 높을수록 혈장 pro-BNP 농도가 높은 의미 있는 양의 상관관계를 보여 주었다(r=0.57, P<0.001). 폰탄 수술시 수술의 위험성을 예견하기 위한 혈장 pro-BNP의 예측인자로서의 유용성을 알아보고자 시행한 ROC 곡선 분석에서 유의한 통계적결과를 얻었다(ROC 곡선 영역 : 0.868, 95% CI : 0.713- 1.023, P<0.01). 폰탄 수술시 위험군을 가려내기 위한 가장 좋은 혈장 pro-BNP 농도의 차단치는 332.4 pg/mL로서, 민감도는 83.3%, 특이도는 82.7%이었다. 심실의 확장말기압력이 높고, 심 흉비가 클수록, 혈중 pro-BNP 농도가 의미 있게 높은 양의 상관관계를 보여 주었다(P<0.001). 결 론 : 폰탄 수술시 중요한 위험인자로 사용되고 있는 폐혈관저항, 폐동맥압력 및 심실이완말기압력 등이 높아짐에 따라, 혈장 pro-BNP 농도가 각각의 위험인자들과 비례하여 높은 값을 나타내는 유의한 양의 상관관계를 보여 주었다. 이는 혈장 pro-BNP 농도가 심실의 기능상태를 나타낼 뿐만 아니라, 폐동맥압력 및 폐혈관저항의 정도까지 동시에 반영해주는 혈역학적 지표로서, 폰탄 수술시 위험률을 평가하는데 하나의 비침습적인 지표로 유용하게 사용할 수 있을 것으로 생각한다.

Keywords

References

  1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971;26:240-8 https://doi.org/10.1136/thx.26.3.240
  2. Gay nor JW, Bridges ND, Cohen MI, Mahle WT, DeCampli WM, Steven JM, et al. Predictors of outcome after the Fontan operation: is hypoplastic left heart syndrome still a risk factor? J Thorac Cardiovasc Surg 2002;123:237-45 https://doi.org/10.1067/mtc.2002.119337
  3. Mair DD, Hagler DJ, Julsrud PR, Puga FJ, Schaff HV, Danielson GK. Early and late results of the modified Fontan procedure for double inlet ventricle : the Mayo Clinic experience. J Am Coll Cardiol 1991;18:1727-32 https://doi.org/10.1016/0735-1097(91)90511-7
  4. Mair DD, Hagler DJ, Puga FJ, Schaff HV, Danielson GK. Fontan operation in 176 patients with tricuspid atresia : results and a proposed new index for patient selection. Circulation 1990;82(5 Suppl):IV164-9 https://doi.org/10.1161/01.CIR.82.1.164
  5. Sanders SP, Wright GB, Keane JF, Norwood WI, Castaneda AR. Clinical and hemodynamic results of the Fontan operation for tricuspid atresia. Am J Cardiol 1982;49:1733- 40 https://doi.org/10.1016/0002-9149(82)90253-3
  6. Cetta F, Feldt RH, O'Leary PW, Mair DD, Warnes CA, Driscoll DJ, et al. Improved early morbidity and mortality after Fontan operation : the Mayo Clinic experience, 1987 to 1992. J Am Coll Cardiol 1996:28:480-6 https://doi.org/10.1016/0735-1097(96)00135-0
  7. Mayer JE Jr, Bridges ND, Lock JE, Hanley FL, Jonas RA, Castaneda AR. Factors associated with marked reduction in mortality for Fontan operations in patients with single ventricle. J Thorac Cardiovasc Surg 1992;103:444-52
  8. Yoshimura N, Yamaguchi M, Oshima Y, Oka S, Ootaki Y, Tei T, et al. Risk factors influencing early and late mortality after total cavopulmonary connection. Eur J Cardiothorac Surg 2001;20:598-602 https://doi.org/10.1016/S1010-7940(01)00857-0
  9. Gentles TL, Mayer JE, Gauvreau K, Newburger JW, Lock JE, Kupferschmid JP. Fontan operation in five hundred consecutive patients : factors influencing early and late outcome. J Thorac Cardiovasc Surg 1997;114:376-91 https://doi.org/10.1016/S0022-5223(97)70183-1
  10. Barmus DA, Driscoll DJ, Offord KP, Humes RA, Mair DD, Schaff HV, et al. The modified Fontan operation for children less than 4 years old. J Am Coll Cardiol 1990;15: 429-35 https://doi.org/10.1016/S0735-1097(10)80073-7
  11. Bridges ND, Mayer JE, Lock JE, Jonas RA, Hanley FL, Kean JF, et al. Effect of baffle fenestraion on outcome of the modified Fontan operation. Circulation 1992;86:1762-9 https://doi.org/10.1161/01.CIR.86.6.1762
  12. Driscoll DJ, Offord K, Feldt R, Schaff H, Puga FJ, Danielson GK. Five- to fifteen-year follow-up after Fontan operation. Circulation 1992;85:469-96 https://doi.org/10.1161/01.CIR.85.2.469
  13. Kopf GS, Kleinman CS, Hijazi ZM, Fahey JT, Dewar ML, Hellenbrand WE. Fenestrated Fontan operation with delayed closure of atrial septal defect. J Thorac Cardiovasc Surg 1992;103:1039-486
  14. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316- 22 https://doi.org/10.1016/S0140-6736(03)13976-1
  15. Bettencourt P. NT-proBNP and BNP : biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63 https://doi.org/10.1016/j.ejheart.2004.01.008
  16. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81 https://doi.org/10.1038/332078a0
  17. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans : evidence for an exquisite dual natriuretic peptide system, ANP and BNP. J Clin Invest 1991;87: 1402-12 https://doi.org/10.1172/JCI115146
  18. Tulevski II, Khatami AD, Groenink M, Wall EE, Romkes H, Mulder BJ. Right ventricular function in congenital cardiac disease : noninvasive quantitative parameters for clinical follow-up. Cardiol Young 2003;13:397-403
  19. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13 https://doi.org/10.1016/S0140-6736(97)03034-1
  20. Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brandao F, Polonia J, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999;69: 169-77 https://doi.org/10.1016/S0167-5273(99)00023-6
  21. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203 https://doi.org/10.1161/01.CIR.90.1.195
  22. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholis MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. Lancet 2000;355:1126-30 https://doi.org/10.1016/S0140-6736(00)02060-2
  23. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:e76
  24. Rauh M, Koch A. Plama N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4 https://doi.org/10.1373/49.9.1563
  25. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide lelvels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8 https://doi.org/10.1016/S0735-1097(98)81518-0
  26. Akagi T, Benson LN, Green M, Ash J, Gilday DL, Williams WG, et al. Ventricular performance before and after Fontan repair for univentricular atrioventricular connection : angiographic and radionuclide assessment. J Am Coll Cardiol 1992;20:920-6 https://doi.org/10.1016/0735-1097(92)90194-R
  27. Hjortdal VE, Stenbog EV, Ravn HB, Emmertsen K, Jensen KT, Pedersen EB, et al. Neurohormonal activation late after cavopulmonary connection. Heart 2000;83:439-43 https://doi.org/10.1136/heart.83.4.439
  28. Tulevski II, Groenink M, Wall EE, Veldhuisen DJ, Boomsma F, Stoker J, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload : correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001;86:27-30 https://doi.org/10.1136/heart.86.1.27
  29. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30 https://doi.org/10.1161/01.HYP.28.1.22
  30. Bolger AP, Sharma R, Li M, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002;106:92-9 https://doi.org/10.1161/01.CIR.0000020009.30736.3F
  31. Hopkins WE, Chen Z, Fukagawa NK, Hall CH, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease. Circulation 2004;109:2872-7 https://doi.org/10.1161/01.CIR.0000129305.25115.80